Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Neuroscience

Merck, Ceverance collaborate to treat Alzheimer’s

by Shi En Kim
August 14, 2022 | A version of this story appeared in Volume 100, Issue 28

 

After a hiatus from the Alzheimer’s drug discovery race, Merck & Co. has returned through a deal with Cerevance to identify novel drug targets for treating the disease. Cerevance will receive $25 million in cash and as much as $1.1 billion in milestones and royalties in exchange for licensing a single discovery-stage program to Merck. Bill Gates–backed Cerevance previously applied its technology to develop a small-molecule drug against Parkinson’s disease, which nailed its Phase 2 trials.

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.